BoironBOIRF 62 Days Payable is 91.67 as of Dec. 2025, which is 23% below its 10-year median of 118.68. GuruFocus rates BOIRF with a GF Score™ of 62/100 and a GF Value™ of $38.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, Boiron ranks better than 53.59% on this metric.
Boiron's average Accounts Payable for the
six
months ended in Dec. 2025 was $41.6 Mil. Boiron's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $82.9 Mil.
Hence, Boiron's Days Payable for the
six
months ended in Dec. 2025 was 91.67.
The historical rank and industry rank for Boiron's Days Payable or its related term are showing as below:
BOIRF'
s Days Payable Range Over the Past 10 Years
Min: 97.74 Med: 118.68 Max: 129.17
Current: 97.74
During the past 13 years, Boiron's highest Days Payable was 129.17. The lowest was 97.74. And the median was 118.68.
BOIRF's Days Payable is ranked better than 53.59% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs BOIRF: 97.74
Boiron's Days Payable
declined
from Dec. 2024 (100.97) to Dec. 2025 (91.67).
It may suggest that Boironaccelerated paying its suppliers.
Boiron Days Payable Related Terms
Boiron Days Payable Historical Data
* Premium members only.
The historical data trend for Boiron's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's Days Payable distribution charts can be found below:
* The bar in red indicates where Boiron's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Boiron's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (BOIRF) has a Days Payable of 91.67 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boiron and its competitors. This is 23% below median its historical median of 118.68. Over the past decade, Boiron's Days Payable has ranged from 97.74 to 129.17. According to the industry distribution chart, Boiron ranks #427 out of 920 companies in the Drug Manufacturers industry, placing it in the top 46.4%.
Is Boiron's Days Payable too high?
Boiron's current Days Payable of 91.67 is 23% below median its 10-year median of 118.68. Over the past 10 years, this metric has ranged from a low of 97.74 to a high of 129.17. The Drug Manufacturers industry median Days Payable is 90.84. Boiron's value of 91.67 is 0.9% above this industry median. Based on the distribution chart, Boiron ranks #427 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Boiron has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Boiron's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #427 out of 920 companies for Days Payable. This puts Boiron in the upper half of its industry. The industry median Days Payable is 90.84. Boiron's value of 91.67 is 0.9% above this benchmark. Historically, Boiron's own Days Payable has ranged from 97.74 to 129.17 over the past decade. While the company's 10-year median is 118.68 vs. the industry median of 90.84, Boiron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current Days Payable of 91.67 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current Days Payable is 91.67, which is 23% below median its own 10-year median of 118.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (BOIRF) is currently considered Fairly Valued. The stock's GF Value™ is $38.49, compared to a current price of $31.90 — trading 17.1% below its estimated fair value. The current Days Payable is 91.67, which is 23% below median its 10-year median of 118.68 and 0.9% above the Drug Manufacturers industry median of 90.84. Boiron's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Boiron (BOIRF), the current Days Payable is 91.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (BOIRF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of $31.90 is trading 17.1% below its estimated GF Value™ of $38.49.
GuruFocus considers Boiron to be Fairly Valued.
Key valuation signals for BOIRF:
Days Payable: 91.67 (23% below median its 10-year median of 118.68)
GF Value™: $38.49 vs. price of $31.90 (17.1% below fair value)
Industry Position: 0.9% above the Drug Manufacturers median (#427 of 920)
No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score
Get the complete analysis for BOIRF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOIRF has been successfully added to your 
